Sort
10,766 grants matching “checkpoint inhibitor”
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$513,608Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
$513,441Jindan Yu · Emory University · R01 · FY2023 · CA
Defining the role of NF1 and SPRED1 loss in melanoma
$513,348Iwei Yeh · University Of California, San Francisco · R37 · FY2025 · CA
DKK2 regulates NK activation and tumor immunity
$513,312Dianqing Wu · Yale University · R01 · FY2021 · CA
DKK2 regulates NK activation and tumor immunity
$513,312Dianqing Wu · Yale University · R01 · FY2018 · CA
DKK2 regulates NK activation and tumor immunity
$513,312Dianqing Wu · Yale University · R01 · FY2020 · CA
Preclinical development and clinical monitoring of adoptive immune therapy
$513,266Jeremy Rose · Division Of Basic Sciences - Nci · ZIC · FY2018 · CA
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$513,261Triparna Sen · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast Cancer
$513,250Yong Zhang · University Of Southern California · R01 · FY2025 · CA
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2022 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2023 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2021 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2024 · AI
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$513,108Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2022 · NS
DNA Methylation Inhibitor Therapy for Testicular Cancer
$513,005Michael J Spinella · University Of Illinois At Urbana-Champaign · R01 · FY2021 · CA
Glutaredoxin, Glutathione Metabolism and Lung Cancer
$512,900Yvonne M.w. Janssen-Heininger · University Of Vermont & St Agric College · R01 · FY2024 · CA
Project 2: Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer
$512,829Barbara Burtness · Yale University · P50 · FY2021 · DE
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$512,817Andre Elias Nel · University Of California Los Angeles · R01 · FY2023 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$512,644Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
$512,562Keith D Robertson · Mayo Clinic Rochester · R01 · FY2024 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$512,558Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
$512,558Alexander V Ljubimov · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Development of novel human Fab probes for PET imaging of macrophages
$512,546Bernadette Marquez-Nostra · University Of Alabama At Birmingham · R01 · FY2024 · EB
Role of Meis1 in Regulation of Cardiomyocyte Proliferation
$512,244Hesham Sadek · Ut Southwestern Medical Center · R01 · FY2016 · HL
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast Cancer
$511,834Yong Zhang · University Of Southern California · R01 · FY2023 · CA